Yanokura M

No ORCID on file · 10 papers in corpus · active 2012-2019

Study types

  • article 2
  • review 2

Condition tags

  • endometriosis 4
  • endometrioma 2
2019
Oncology reports ·doi:10.3892/or.2019.7353

Endometrial polyps are common, yet the molecular mechanisms underlying their formation and progression remain unclear. We examined gene mutations possibly related to the pathogenesis of endometrial polyps, as well as to their clinical featu…

2017
Oncology letters ·doi:10.3892/ol.2017.6891

Epigenetic regulatory mechanisms are a current focus in studies investigating cancer. Chromatin remodeling alters chromatin structure and regulates gene expression, and aberrant chromatin remodeling is involved in carcinogenesis. AT-rich in…

2017
Oncology letters ·doi:10.3892/ol.2017.5582

Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross-sectional genome-wide analysis of num…

review 2016
Oncology reports ·doi:10.3892/or.2015.4421

The AT-rich interacting domain‑containing protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) vi…

article 2016
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.13137

AIM: Micro ribonucleic acids (miRNAs) play an important pathological role in endometriosis. Leuprolide acetate, an analog of gonadotropin-releasing hormone, is widely used to treat endometriosis; however, the molecular mechanisms involved i…

article 2015
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.12768

AIM: Leuprolide acetate, an analog of gonadotropin-releasing hormone (GnRH), regresses endometriotic tissue and reduces pain, resulting in clinical improvement upon treatment. The molecular mechanisms involved in the regression of endometri…

2015
EXCLI journal ·doi:10.17179/excli2014-590

Endometrial cancer is a common malignant gynecological tumor, but there are few biomarkers that are useful for early and accurate diagnosis and few treatments other than surgery. However, use of microRNAs (miRNAs) that induces gene downregu…

2014
Molecular and clinical oncology ·doi:10.3892/mco.2014.397

Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9-2.7%. Lynch syndrome accounts for 10-15% of hereditary ovarian cancers, while hereditary breast and ovarian cancer syndrome accounts for 65-75% of these cancers. The lif…

2013
Oncology reports ·doi:10.3892/or.2013.2221

Cases of endometrial cancer have increased in recent years, but the prognosis of patients with this disease has also been improved by combined modality therapy with surgery, radiotherapy and chemotherapy. However, th…

review 2012
International journal of oncology ·doi:10.3892/ijo.2012.1384

Progestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effect…